Matthew Caufield
Stock Analyst at HC Wainwright & Co.
(4.62)
# 240
Out of 5,031 analysts
120
Total ratings
55.56%
Success rate
31.39%
Average return
Main Sectors:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZBIO Zenas BioPharma | Reiterates: Buy | $30 | $23.95 | +25.26% | 4 | Oct 9, 2025 | |
| IMUX Immunic | Reiterates: Buy | $10 | $0.80 | +1,149.53% | 5 | Sep 26, 2025 | |
| ADVM Adverum Biotechnologies | Reiterates: Buy | $30 | $4.29 | +599.30% | 7 | Sep 23, 2025 | |
| FBLG FibroBiologics | Reiterates: Buy | $10 | $0.40 | +2,395.01% | 6 | Sep 12, 2025 | |
| MLYS Mineralys Therapeutics | Reiterates: Buy | $42 | $43.56 | -3.58% | 11 | Sep 8, 2025 | |
| KOD Kodiak Sciences | Maintains: Neutral | $3 → $5 | $14.10 | -64.54% | 5 | Aug 18, 2025 | |
| DMAC DiaMedica Therapeutics | Reiterates: Buy | $12 | $6.58 | +82.37% | 7 | Aug 15, 2025 | |
| LYRA Lyra Therapeutics | Reiterates: Neutral | $16 | $6.90 | +131.82% | 9 | Aug 14, 2025 | |
| LENZ LENZ Therapeutics | Maintains: Buy | $48 → $56 | $38.26 | +46.37% | 7 | Aug 1, 2025 | |
| IRD Opus Genetics | Reiterates: Buy | $8 | $1.87 | +327.81% | 4 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $10 | $5.03 | +98.81% | 1 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $12.96 | +54.32% | 10 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $8 | $2.93 | +173.04% | 1 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $72 | $72.93 | -1.28% | 1 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $5.26 | +90.11% | 13 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $13.58 | +135.64% | 3 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $3.41 | -41.35% | 7 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $9.84 | +265.85% | 18 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $409.90 | -93.17% | 1 | Aug 22, 2023 |
Zenas BioPharma
Oct 9, 2025
Reiterates: Buy
Price Target: $30
Current: $23.95
Upside: +25.26%
Immunic
Sep 26, 2025
Reiterates: Buy
Price Target: $10
Current: $0.80
Upside: +1,149.53%
Adverum Biotechnologies
Sep 23, 2025
Reiterates: Buy
Price Target: $30
Current: $4.29
Upside: +599.30%
FibroBiologics
Sep 12, 2025
Reiterates: Buy
Price Target: $10
Current: $0.40
Upside: +2,395.01%
Mineralys Therapeutics
Sep 8, 2025
Reiterates: Buy
Price Target: $42
Current: $43.56
Upside: -3.58%
Kodiak Sciences
Aug 18, 2025
Maintains: Neutral
Price Target: $3 → $5
Current: $14.10
Upside: -64.54%
DiaMedica Therapeutics
Aug 15, 2025
Reiterates: Buy
Price Target: $12
Current: $6.58
Upside: +82.37%
Lyra Therapeutics
Aug 14, 2025
Reiterates: Neutral
Price Target: $16
Current: $6.90
Upside: +131.82%
LENZ Therapeutics
Aug 1, 2025
Maintains: Buy
Price Target: $48 → $56
Current: $38.26
Upside: +46.37%
Opus Genetics
Jun 27, 2025
Reiterates: Buy
Price Target: $8
Current: $1.87
Upside: +327.81%
Jun 18, 2025
Assumes: Buy
Price Target: $10
Current: $5.03
Upside: +98.81%
Jun 9, 2025
Reiterates: Buy
Price Target: $20
Current: $12.96
Upside: +54.32%
Jun 4, 2025
Assumes: Buy
Price Target: $8
Current: $2.93
Upside: +173.04%
May 27, 2025
Assumes: Buy
Price Target: $72
Current: $72.93
Upside: -1.28%
May 19, 2025
Reiterates: Buy
Price Target: $10
Current: $5.26
Upside: +90.11%
May 12, 2025
Reiterates: Buy
Price Target: $32
Current: $13.58
Upside: +135.64%
Mar 25, 2025
Downgrades: Neutral
Price Target: $12 → $2
Current: $3.41
Upside: -41.35%
Mar 3, 2025
Reiterates: Buy
Price Target: $36
Current: $9.84
Upside: +265.85%
Aug 22, 2023
Reiterates: Buy
Price Target: $28
Current: $409.90
Upside: -93.17%